バイオシミラーの世界市場レポート 2024

バイオシミラーの市場規模は、今後数年間で急速に成長すると予想されています。 2028年には17.4%の年間複合成長率（CAGR）で358億1,000万米ドルに成長すると予想されます。予測される成長の原動力は、癌の有病率の増加、顆粒球コロニー刺激因子（G-CSF）予防に対する需要の高まり、医療費の増加、新興国の大きな可能性、技術の進歩、生物学的製剤の普及、人口の高齢化、医療アクセスの改善などの要因です。予測期間における主な動向としては、革新的な医薬品の研究開発への注力、成長のためのM&Aの重視、戦略的パートナーシップの確立、投資の増加、人工知能の活用などが挙げられます。

バイオシミラー市場は、関節炎、喘息、がんなどの慢性疾患の蔓延により、大幅な成長が見込まれています。長時間労働、限られた身体活動、不健康なライフスタイルの選択などの要因がこれらの症状の発生増加に寄与しており、バイオシミラーが治療の選択肢として好まれることが増えています。 バイオシミラーは、がん細胞に対する免疫系の反応を刺激し、体からのがん細胞の除去を助ける上で重要な役割を果たします。国連の予測によると、2030年までに慢性疾患が世界の死亡の約70%を占めると推定され、慢性疾患による世界の負担は約60%に達すると予想されています。その結果、この慢性疾患有病率の急増によりバイオシミラーの需要が高まり、その結果バイオシミラー市場が推進されることになります。

ヘルスケア費の上昇軌道は、バイオシミラー市場の拡大の触媒となる準備が整っています。ヘルスケア支出には、特定の人口またはヘルスケアシステム内でのヘルスケア製品およびサービスに対する支出の合計が含まれます。バイオシミラー製品は、高価な生物学的製剤に代わるより費用対効果の高い代替品を提供することでヘルスケア支出の抑制に貢献し、それによって患者とヘルスケアシステムの両方の治療費を削減します。たとえば、英国に本拠を置く国家統計局の2023年 5月の報告書によると、英国のヘルスケア支出は2020年から2021年の間に名目9.4%増加、実質9.7%増加しました。このヘルスケア支出の急増はバイオシミラー市場の成長の原動力となっています。

目次

第1章 エグゼクティブサマリー

第2章 市場の特徴

第3章 市場動向と戦略

第4章 マクロ経済シナリオ

• 高インフレが市場に与える影響
• ウクライナ・ロシア戦争が市場に与える影響
• COVID-19による市場への影響

第5章 世界市場規模と成長

• 世界の市場促進要因と抑制要因
  • 市場促進要因
  • 市場抑制要因
• 世界の市場規模実績と成長、2018年～2023年
• 世界の市場規模予測と成長、2023年～2028年、2033年

第6章 市場セグメンテーション

• 世界のバイオシミラー市場、タイプ別セグメンテーション、実績および予測、2018-2023、2023-2028年、2033年
• モノクローナル抗体
• インスリン
• エリスロポエチン
• 顆粒球コロニー刺激因子
• その他のホルモン
• その他のタイプ
• 世界のバイオシミラー市場、製品別セグメンテーション、実績および予測、2018-2023、2023-2028年、2033年
• 組換え非グリコシル化タンパク質
• 組換えグリコシル化タンパク質
• 世界のバイオシミラー市場、用途別セグメンテーション、実績および予測、2018-2023、2023-2028年、2033年
• 腫瘍学
• 慢性疾患および自己免疫疾患
• 成長ホルモン欠乏症
• 感染症
• その他の用途

第7章 地域および国の分析

• 世界のバイオシミラー市場、地域別、実績および予測、2018-2023、2023-2028年、2033年
• 世界のバイオシミラー市場、国別、実績および予測、2018-2023、2023-2028年、2033年

第8章 アジア太平洋市場

第9章 中国市場

第10章 インド市場

第11章 日本市場

第12章 オーストラリア市場

第13章 インドネシア市場

第14章 韓国市場

第15章 西欧市場

第16章 英国市場

第17章 ドイツ市場

第18章 フランス市場

第19章 イタリア市場

第20章 スペイン市場

第21章 東欧市場

第22章 ロシア市場

第23章 北米市場

第24章 米国市場

第25章 カナダ市場

第26章 南米市場

第27章 ブラジル市場

第28章 中東市場

第29章 アフリカ市場

第30章 競合情勢と企業プロファイル

• バイオシミラー市場の競合情勢
• バイオシミラー市場の企業プロファイル
  • Amgen
  • Pfizer
  • Novartis AG
  • Samsung Bioepis Co., Ltd.
  • Viatris

第31章 その他の大手および革新的な企業

• Biocon
• Celltrion, Inc.
• Coherus Biosciences
• Elli Lilly and Company
• Dr. Reddy's Laboratories
• Roche India Pvt Ltd
• Abbott India Limited
• bioMerieux India
• Becton Dickinson Private Limited
• Danaher Corporation
• Wuxi biologics
• shanghai Henlius biotech
• Innovent Biologics
• Hisun Pharma
• 3SBio

第32章 競合ベンチマーキング

第33章 競合ダッシュボード

第34章 主要な合併と買収

第35章 将来の見通しと可能性の分析

第36章 付録

Biosimilars are medications made from living things, though they can be made in a variety of ways and with slightly different materials. Due to the intricacy and high cost of their creation, as well as their molecular size and structure, biosimilars are fundamentally distinct from generic drugs.

The main types of biosimilars are human growth hormone, erythropoietin, monoclonal antibodies, insulin, interferon, granulocyte-colony stimulating factor, and others. Erythropoietin is a hormone produced by the kidneys to stimulate the production and maintenance of vital red blood cells. The various products include recombinant non-glycosylated proteins and recombinant glycosylated proteins that are used for the treatment of oncology, chronic and autoimmune diseases, growth hormone deficiency, infectious diseases, and others.

The biosimilars market research report is one of a series of new reports from The Business Research Company that provides biosimilars market statistics, including biosimilars industry global market size, regional shares, competitors with a biosimilars market share, detailed biosimilars market segments, market trends, and opportunities, and any further data you may need to thrive in the biosimilars industry. This biosimilars market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

The biosimilars market size has grown rapidly in recent years. It will grow from $15.86 billion in 2023 to $18.85 billion in 2024 at a compound annual growth rate (CAGR) of 18.9%. The growth observed during the historic period can be attributed to factors such as an increase in cancer prevalence, robust economic growth in emerging markets, a rise in pharmaceutical research and development (R&D) expenditure, increased healthcare spending, growing government initiatives, a strong pipeline of drugs, the cost-effectiveness of biosimilars, and an increase in patent expiration.

The biosimilars market size is expected to see rapid growth in the next few years. It will grow to $35.81 billion in 2028 at a compound annual growth rate (CAGR) of 17.4%. The forecasted growth is driven by factors such as the increasing prevalence of cancer, rising demand for granulocyte colony-stimulating factor (G-CSF) prophylaxis, higher healthcare expenditure, the significant potential of emerging economies, technological advancements, widespread use of biological drugs, an aging population, and improved healthcare access. Key trends in the forecast period include a focus on robust research and development for innovative drugs, emphasis on mergers and acquisitions for growth, establishment of strategic partnerships, increased investments, and utilization of artificial intelligence.

The biosimilars market is anticipated to witness significant growth due to the escalating prevalence of chronic diseases such as arthritis, asthma, and cancer. Factors such as prolonged work hours, limited physical activity, and unhealthy lifestyle choices contribute to the increased occurrence of these conditions, for which biosimilars are increasingly becoming a preferred treatment option. Biosimilars play a crucial role in stimulating the immune system response against cancer cells, aiding in their elimination from the body. As per a United Nations projection, by 2030, chronic diseases are estimated to account for around 70% of global deaths, with the global burden of chronic disease expected to reach approximately 60%. Consequently, this upsurge in chronic disease prevalence is set to drive the demand for biosimilars, consequently propelling the biosimilars market.

The upward trajectory of healthcare expenditures is poised to be a catalyst for the expansion of the biosimilars market. Healthcare expenditures encompass the total spending on healthcare goods and services within a specific population or healthcare system. Biosimilar products contribute to curbing healthcare expenditures by providing more cost-effective alternatives to expensive biologic drugs, thereby reducing treatment expenses for both patients and healthcare systems. For example, according to a report from the UK-based Office for National Statistics in May 2023, healthcare spending in the UK witnessed a nominal increase of 9.4% and a real increase of 9.7% between 2020 and 2021. This surge in healthcare expenditures is a driving force behind the growth of the biosimilars market.

Key players in the biosimilars market are heavily invested in pioneering innovative products to establish a competitive edge. Notably, AMJEVITA marks a significant milestone as the inaugural U.S. biosimilar to Humira, a medication relied upon by over a million patients managing severe inflammatory conditions. In January 2023, Amgen Inc., a prominent biotechnology company, introduced AMJEVITA (adalimumab-atto) into the U.S. market. This biosimilar, available at 55% and 5% below the list price of Humira, offers patients a more cost-effective option.

Major companies within the biosimilars domain persist in crafting novel solutions. FYLNETRA represents a leap forward as a leukocyte growth factor designed to lower infection incidence, particularly febrile neutropenia, in patients with non-myeloid malignancies undergoing myelosuppressive anti-cancer treatments. In May 2023, Amneal Pharmaceuticals Inc., a distinguished pharmaceutical entity, launched the commercial debut of FYLNETRA (pegfilgrastim-pbbk), a Neulasta-referenced biosimilar delivered in a pre-filled single-dose syringe. FYLNETRA aims to address neutropenia, commonly experienced by chemotherapy patients, presenting a significant advancement in biosimilar-based treatments.

In November 2022, Biocon Biologics Ltd., an Indian biopharmaceutical company, announced the acquisition of Viatris Inc.'s biosimilars business for $3 billion. This strategic move aims to enhance Biocon Biologics' proximity to patients, customers, and payors by providing direct commercial capabilities and supporting infrastructure in advanced countries and various emerging regions. The merger combines Viatris' acquired global biosimilars business with Biocon Biologics' existing capabilities in research and development, global-scale manufacturing, and commercialization. Viatris Inc. is a US-based pharmaceutical company specializing in the development, licensing, manufacturing, marketing, and distribution of generic and branded medicines.

Major companies operating in the biosimilars market report are Amgen, Pfizer, Novartis AG, Samsung Bioepis Co., Ltd., Viatris, Biocon, Celltrion, Inc., Coherus Biosciences, Elli Lilly and Company, Dr. Reddy's Laboratories, Roche India Pvt Ltd., Abbott India Limited, bioMerieux India, Becton Dickinson Private Limited, Danaher Corporation, Wuxi biologics, shanghai Henlius biotech, Innovent Biologics, Hisun Pharma, 3SBio, Beijing ShuangLu Pharmaceuticals, Qilu Pharmaceutical, Mylan, Kyowa Hakko Kirin, Takeda, Mitsubishi Tanabe, AGC Biologics, Bio-Thera, Sandoz Pty Ltd., Apotex Pty Ltd., Cadila Pharmaceuticals, BiosanaPharma, GlaxoSmithKline, AstraZeneca, Bayer, Merck, Boehringer Ingelheim, Sanofi, Fresenius Kabi, Napp Pharmaceuticals, Mundipharma Deutschland GmbH & Co. KG, HARMONIE MEDICAL SERVICE Saint-Benoit, INSULET FRANCE SAS Paris, Microgen, Geropharm, Valenta, NovaMedica, SynBio, Rani Therapeutics, Emisphere Technologies, Inc., Enteris BioPharma, Allena Pharmaceuticals, Abbvie, Johnson & Johnson, Biogen Inc., Ache, Eurofarma, Teva Pharmaceuticals, Oramed Pharmaceuticals, Entera Bio, Julphar, Hikma Pharmaceuticals, BIOPHARMA-MEA, NeoTX, AID Genomics Limited, Altis Biologics, Cipla Medpro South Africa, Next Biosciences, Viome, Inqaba Biotechnical Industries (Pty)

North America was the largest region in the global biosimilars market in 2023. Middle East is expected to be the fastest growing region in the forecast period. The regions covered in the biosimilars market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa

The countries covered in the biosimilars market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Italy, Canada, Spain

The biosimilars market consists of sales of binocrit, epoetin alfa hexal, and abseamed. Values in this market are factory gate values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Biosimilars Global Market Report 2024 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on biosimilars market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

• Gain a truly global perspective with the most comprehensive report available on this market covering 50+ geographies.
• Understand how the market has been affected by the coronavirus and how it is responding as the impact of the virus abates.
• Assess the Russia - Ukraine war's impact on agriculture, energy and mineral commodity supply and its direct and indirect impact on the market.
• Measure the impact of high global inflation on market growth.
• Create regional and country strategies on the basis of local data and analysis.
• Identify growth segments for investment.
• Outperform competitors using forecast data and the drivers and trends shaping the market.
• Understand customers based on the latest market shares.
• Benchmark performance against key competitors.
• Suitable for supporting your internal and external presentations with reliable high quality data and analysis
• Report will be updated with the latest data and delivered to you within 3-5 working days of order along with an Excel data sheet for easy data extraction and analysis.
• All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for biosimilars? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The biosimilars market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

• The market characteristics section of the report defines and explains the market.
• The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
• The forecasts are made after considering the major factors currently impacting the market. These include:

The impact of sanctions, supply chain disruptions, and altered demand for goods and services due to the Russian Ukraine war, impacting various macro-economic factors and parameters in the Eastern European region and its subsequent effect on global markets.

The impact of higher inflation in many countries and the resulting spike in interest rates.

The continued but declining impact of covid 19 on supply chains and consumption patterns.

• Market segmentations break down the market into sub markets.
• The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
• The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
• The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.

Scope

Markets Covered:

• 1) By Type: Monoclonal Antibodies; Insulin; Erythropoietin; Granulocyte-Colony Stimulating Factor; Other Hormones; Others
• 2) By Product: Recombinant Non-glycosylated Proteins; Recombinant Glycosylated Proteins
• 3) By Application: Oncology; Chronic And Autoimmune Diseases; Growth Hormone Deficiency; Infectious Diseases; Other Applications
• Companies Mentioned: Amgen; Pfizer; Novartis AG; Samsung Bioepis Co., Ltd.; Viatris
• Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
• Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
• Time series: Five years historic and ten years forecast.
• Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
• Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.
• Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
• Delivery Format: PDF, Word and Excel Data Dashboard.

Table of Contents

1. Executive Summary

2. Biosimilars Market Characteristics

3. Biosimilars Market Trends And Strategies

4. Biosimilars Market - Macro Economic Scenario

• 4.1. Impact Of High Inflation On The Market
• 4.2. Ukraine-Russia War Impact On The Market
• 4.3. COVID-19 Impact On The Market

5. Global Biosimilars Market Size and Growth

• 5.1. Global Biosimilars Market Drivers and Restraints
  • 5.1.1. Drivers Of The Market
  • 5.1.2. Restraints Of The Market
• 5.2. Global Biosimilars Historic Market Size and Growth, 2018 - 2023, Value ($ Billion)
• 5.3. Global Biosimilars Forecast Market Size and Growth, 2023 - 2028, 2033F, Value ($ Billion)

6. Biosimilars Market Segmentation

• 6.1. Global Biosimilars Market, Segmentation By Types, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• Monoclonal Antibodies
• Insulin
• Erythropoietin
• Granulocyte-Colony Stimulating Factor
• Other Hormones
• Other Types
• 6.2. Global Biosimilars Market, Segmentation By Product, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• Recombinant Non-glycosylated Proteins
• Recombinant Glycosylated Proteins
• 6.3. Global Biosimilars Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• Oncology
• Chronic and Autoimmune Diseases
• Growth Hormone Deficiency
• Infectious Diseases
• Other Applications

7. Biosimilars Market Regional And Country Analysis

• 7.1. Global Biosimilars Market, Split By Region, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 7.2. Global Biosimilars Market, Split By Country, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

8. Asia-Pacific Biosimilars Market

• 8.1. Asia-Pacific Biosimilars Market Overview
• Region Information, Impact Of COVID-19, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 8.2. Asia-Pacific Biosimilars Market, Segmentation By Types, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 8.3. Asia-Pacific Biosimilars Market, Segmentation By Product, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 8.4. Asia-Pacific Biosimilars Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

9. China Biosimilars Market

• 9.1. China Biosimilars Market Overview
• 9.2. China Biosimilars Market, Segmentation By Types, Historic and Forecast, 2018-2023, 2023-2028F, 2033F,$ Billion
• 9.3. China Biosimilars Market, Segmentation By Product, Historic and Forecast, 2018-2023, 2023-2028F, 2033F,$ Billion
• 9.4. China Biosimilars Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F,$ Billion

10. India Biosimilars Market

• 10.1. India Biosimilars Market, Segmentation By Types, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 10.2. India Biosimilars Market, Segmentation By Product, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 10.3. India Biosimilars Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

11. Japan Biosimilars Market

• 11.1. Japan Biosimilars Market Overview
• 11.2. Japan Biosimilars Market, Segmentation By Types, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 11.3. Japan Biosimilars Market, Segmentation By Product, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 11.4. Japan Biosimilars Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

12. Australia Biosimilars Market

• 12.1. Australia Biosimilars Market, Segmentation By Types, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 12.2. Australia Biosimilars Market, Segmentation By Product, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 12.3. Australia Biosimilars Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

13. Indonesia Biosimilars Market

• 13.1. Indonesia Biosimilars Market, Segmentation By Types, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 13.2. Indonesia Biosimilars Market, Segmentation By Product, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 13.3. Indonesia Biosimilars Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

14. South Korea Biosimilars Market

• 14.1. South Korea Biosimilars Market Overview
• 14.2. South Korea Biosimilars Market, Segmentation By Types, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 14.3. South Korea Biosimilars Market, Segmentation By Product, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 14.4. South Korea Biosimilars Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

15. Western Europe Biosimilars Market

• 15.1. Western Europe Biosimilars Market Overview
• 15.2. Western Europe Biosimilars Market, Segmentation By Types, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 15.3. Western Europe Biosimilars Market, Segmentation By Product, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 15.4. Western Europe Biosimilars Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

16. UK Biosimilars Market

• 16.1. UK Biosimilars Market, Segmentation By Types, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 16.2. UK Biosimilars Market, Segmentation By Product, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 16.3. UK Biosimilars Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

17. Germany Biosimilars Market

• 17.1. Germany Biosimilars Market, Segmentation By Types, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 17.2. Germany Biosimilars Market, Segmentation By Product, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 17.3. Germany Biosimilars Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

18. France Biosimilars Market

• 18.1. France Biosimilars Market, Segmentation By Types, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 18.2. France Biosimilars Market, Segmentation By Product, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 18.3. France Biosimilars Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

19. Italy Biosimilars Market

• 19.1. Italy Biosimilars Market, Segmentation By Types, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 19.2. Italy Biosimilars Market, Segmentation By Product, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 19.3. Italy Biosimilars Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

20. Spain Biosimilars Market

• 20.1. Spain Biosimilars Market, Segmentation By Types, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 20.2. Spain Biosimilars Market, Segmentation By Product, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 20.3. Spain Biosimilars Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

21. Eastern Europe Biosimilars Market

• 21.1. Eastern Europe Biosimilars Market Overview
• 21.2. Eastern Europe Biosimilars Market, Segmentation By Types, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 21.3. Eastern Europe Biosimilars Market, Segmentation By Product, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 21.4. Eastern Europe Biosimilars Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

22. Russia Biosimilars Market

• 22.1. Russia Biosimilars Market, Segmentation By Types, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 22.2. Russia Biosimilars Market, Segmentation By Product, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 22.3. Russia Biosimilars Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

23. North America Biosimilars Market

• 23.1. North America Biosimilars Market Overview
• 23.2. North America Biosimilars Market, Segmentation By Types, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 23.3. North America Biosimilars Market, Segmentation By Product, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 23.4. North America Biosimilars Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

24. USA Biosimilars Market

• 24.1. USA Biosimilars Market Overview
• 24.2. USA Biosimilars Market, Segmentation By Types, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 24.3. USA Biosimilars Market, Segmentation By Product, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 24.4. USA Biosimilars Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

25. Canada Biosimilars Market

• 25.1. Canada Biosimilars Market Overview
• 25.2. Canada Biosimilars Market, Segmentation By Types, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 25.3. Canada Biosimilars Market, Segmentation By Product, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 25.4. Canada Biosimilars Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

26. South America Biosimilars Market

• 26.1. South America Biosimilars Market Overview
• 26.2. South America Biosimilars Market, Segmentation By Types, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 26.3. South America Biosimilars Market, Segmentation By Product, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 26.4. South America Biosimilars Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

27. Brazil Biosimilars Market

• 27.1. Brazil Biosimilars Market, Segmentation By Types, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 27.2. Brazil Biosimilars Market, Segmentation By Product, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 27.3. Brazil Biosimilars Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

28. Middle East Biosimilars Market

• 28.1. Middle East Biosimilars Market Overview
• 28.2. Middle East Biosimilars Market, Segmentation By Types, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 28.3. Middle East Biosimilars Market, Segmentation By Product, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 28.4. Middle East Biosimilars Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

29. Africa Biosimilars Market

• 29.1. Africa Biosimilars Market Overview
• 29.2. Africa Biosimilars Market, Segmentation By Types, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 29.3. Africa Biosimilars Market, Segmentation By Product, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 29.4. Africa Biosimilars Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

30. Biosimilars Market Competitive Landscape And Company Profiles

• 30.1. Biosimilars Market Competitive Landscape
• 30.2. Biosimilars Market Company Profiles
  • 30.2.1. Amgen
    • 30.2.1.1. Overview
    • 30.2.1.2. Products and Services
    • 30.2.1.3. Strategy
    • 30.2.1.4. Financial Performance
  • 30.2.2. Pfizer
    • 30.2.2.1. Overview
    • 30.2.2.2. Products and Services
    • 30.2.2.3. Strategy
    • 30.2.2.4. Financial Performance
  • 30.2.3. Novartis AG
    • 30.2.3.1. Overview
    • 30.2.3.2. Products and Services
    • 30.2.3.3. Strategy
    • 30.2.3.4. Financial Performance
  • 30.2.4. Samsung Bioepis Co., Ltd.
    • 30.2.4.1. Overview
    • 30.2.4.2. Products and Services
    • 30.2.4.3. Strategy
    • 30.2.4.4. Financial Performance
  • 30.2.5. Viatris
    • 30.2.5.1. Overview
    • 30.2.5.2. Products and Services
    • 30.2.5.3. Strategy
    • 30.2.5.4. Financial Performance

31. Biosimilars Market Other Major And Innovative Companies

• 31.1. Biocon
• 31.2. Celltrion, Inc.
• 31.3. Coherus Biosciences
• 31.4. Elli Lilly and Company
• 31.5. Dr. Reddy's Laboratories
• 31.6. Roche India Pvt Ltd
• 31.7. Abbott India Limited
• 31.8. bioMerieux India
• 31.9. Becton Dickinson Private Limited
• 31.10. Danaher Corporation
• 31.11. Wuxi biologics
• 31.12. shanghai Henlius biotech
• 31.13. Innovent Biologics
• 31.14. Hisun Pharma
• 31.15. 3SBio

32. Global Biosimilars Market Competitive Benchmarking

33. Global Biosimilars Market Competitive Dashboard

34. Key Mergers And Acquisitions In The Biosimilars Market

35. Biosimilars Market Future Outlook and Potential Analysis

• 35.1 Biosimilars Market In 2028 - Countries Offering Most New Opportunities
• 35.2 Biosimilars Market In 2028 - Segments Offering Most New Opportunities
• 35.3 Biosimilars Market In 2028 - Growth Strategies
  • 35.3.1 Market Trend Based Strategies
  • 35.3.2 Competitor Strategies

36. Appendix

• 36.1. Abbreviations
• 36.2. Currencies
• 36.3. Historic And Forecast Inflation Rates
• 36.4. Research Inquiries
• 36.5. The Business Research Company
• 36.6. Copyright And Disclaimer